CA
PACB icon

Clearstead Advisors’s Pacific Biosciences PACB Stock Holding History

Clearstead Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$175 Buy
+104
New +$151 ﹤0.01% 3236

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Clearstead Advisors's PACB Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Pacific Biosciences (PACB) in Q2 2026: 104 shares worth $175. The stake represents ﹤0.01% of the portfolio and ranks #3236 among its holdings.

223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Clearstead Advisors held 104 shares of Pacific Biosciences worth $175 as of Q2 2026.
  • Pacific Biosciences was a new Clearstead Advisors position in Q2 2026.
  • Pacific Biosciences made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3236 holding.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.